@article{563c6ebfd01f48d78435bf91ddcffafb,
title = "Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation",
abstract = "Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with resected stage I to III non-small-cell lung cancer (NSCLC) harbouring an activating EGFR mutation.",
author = "Mario Occhipinti and Roberto Ferrara and Martina Imbimbo and Vittorio Simeon and Giulia Fiscon and Corynne Marchal and Nicole Skoetz and Giuseppe Viscardi",
note = "Funding Information: We thank Fran{\c c}ois Calais, Information Specialist of Cochrane Lung Cancer, for providing the search strategies and Jessica Sharp for her copy-editing work. We thank the following individuals for their comments on this protocol. Jacques Cadranel, MD PhD (Chest and Thoracic Oncology Department, APHP Tenon Hospital and Sorbonne University, Paris, France) Cheryl Ho, MD (Vancouver, British Columbia) John C Rusckdeschel, MD Mia Schmidt-Hansen, Fergus Macbeth and Virginie Westeel (Cochrane Lung Cancer) Jacques Cadranel, MD PhD (Chest and Thoracic Oncology Department, APHP Tenon Hospital and Sorbonne University, Paris, France) Cheryl Ho, MD (Vancouver, British Columbia) John C Rusckdeschel, MD Mia Schmidt-Hansen, Fergus Macbeth and Virginie Westeel (Cochrane Lung Cancer) Publisher Copyright: Copyright {\textcopyright} 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.",
year = "2022",
month = mar,
day = "18",
doi = "10.1002/14651858.CD015140",
language = "English",
volume = "2022",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "3",
}